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ABSTRACT

Radioactive microspheres for radiation synovectomy of
arthritic joints in a mammal comprises a biodegradable
glass material and a beta radiation emitting radioisotope
chemically dissolved in and distributed substantially
uniformly throughout the glass material. The biode
gradable glass material may be lithium silicate, lithium
aluminosilicate, lithium aluminoborate, lithium germanate, lithium aluminogermanate, potassium silicate, po
tassium aluminosilicate, potassium aluminoborate, po
tassium germanate or potassium aluminogermanate and
the beta radiation emitting radioisotope may be samari
um-153, holmium-166, erbium-169, dysprosium-165,
rhenium-186, rhenium-188 or yttrium-90. Method for
preparing such microspheres and for carrying out radia
tion synovectomy of arthritic joints utilizing such mi
crospheres are also disclosed.
19 Claims, 2 Drawing Sheets
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COMPOSITION AND METHOD FOR RADIATION
SYNOVECTOMY OF ARTHRITIC JOINTS
This is a division of application Ser. No. 150,154, filed 5
Jan. 29, 1988, now U.S. Pat. No. 4,889,707.
BACKGROUND OF THE INVENTION
This invention relates to radiation synovectomy for
arthritic joints and, more particularly, to novel biode
gradable and biologically compatible glass micro
spheres or beads and their use in carrying out radiation
synovectomy of arthritic joints.
Current medical management of rheumatoid arthritis
includes patient education, appropriate rest and physi
cal therapy, and the use of anti-inflammatory drugs for
relief of pain and inflammation. Ruddy, S., The Man
agement of Rheumatoid Arthritis. Textbook of Rheu
matology, 2nd ed., W. B. Saunders Co. Philadelphia,
1985, p. 979. Patients who do not respond to these mo
dalities may require therapy With anti-malarial agents
such as hydroxychloroquine (Dell, C.L., Hydroxychlo
roquine Sulfate in Rheumatoid Arthritis: Long-Term
Response Rate and Predictive Parameters, American
Journal of Medicine, 75:46, 1983) or remission inducing
agents including gold salts (Empire Rheumatism Coun
cil, Gold Therapy in Rheumatoid Arthritis: Final Re
port of a Multicentre Controlled Trial, Ann. Rheum.
Dis. 20:315, 1961), penicillamine (Multicentre Trial
Group: Controlled Trial of d(-) Penicillamine in Severe
Rheumatoid Arthritis, Lancet, 1:275, 1973), or azathioprine (Abel, T. et al., Long-Term Effects of Azathioprine in Rheumatoid Arthritis, Arthritis Rheum. 21:539,
1978). Despite the efficacy of these drugs, patient re
sponse is variable and improvement may not occur until
treatment has extended for three to six months. When a
few joints remain swollen and painful and interfere with
the patient’s progress, intra-articular instillation of corti
costeroids may be used as an adjunct to systemic ther
apy. This local remedy, however, may be ineffective or
may last only a few days (Owen, D.S., Aspiration and
Injection of Joints and Soft Tissues, Textbook of Rheu
matology, supra, p 546).
Surgery may be used in several different ways to help
the patient with rheumatoid arthritis. Surgery can help
relieve pain, it can prevent further deformity and loss of
function, or at least allay these problems, and when
destruction has occurred, reconstructive procedures
can return function to a part or a limb. Sledge, C.B.,
Introduction to the Surgical Management of Arthritis,
Textbook of Rheumatology, supra, p. 1787.
Most of the operations done on rheumatoid patients
relieve pain. Fusions of joints, total joint replacement
and synovectomy are examples of procedures that sig
nificantly reduce pain. Conaty (Conaty, J.P., Surgery of
the Hip and Knee in Patients with Rheumatoid Arthri
tis, Journal of Bone and Joint Surgery, 55(A):301, 1973)
states that in rheumatoid arthritis, synovectomy was the
most successful procedure for preserving motion of a
joint, except for total joint arthroplasty. This proce
dure, then, is preventive. Even so, eventually the syno
vium regenerates and the process continues (Patzakis,
M.J. et al., A Visual, Histological, and Enzymatic Study
of Regenerating Rheumatoid Synovium in the Synovectomized Knee, Journal of Bone and Joint Surgery,
55(A):287, 1973). Total joint surgery will relieve any or
all of the afore-mentioned disabilities, but brings with it
other problems that must be taken into consideration by
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the surgeon. Some of these are: 1) cost, 2) the risk of
infection, 3) the fact that the implants may come loose
and be painful, and 4) the fact that the implant may
break with unusual use.
Chemical and radioisotope synovectomy (synoviorthesis) constitutes an effective alternative to operative
therapy. The advantages of synoviorthesis are: 1) simple
techniques employed in their use, 2 ) decreased or no
hospitalization, 3) lower costs, 4) early and easier mobi
lization of the patient, and 5) a surgical synovectomy
remains an alternative treatment should the synovior
thesis not work.
In general, the results of radioisotope synoviorthesis
appear to be superior to those attained with chemical
synovectomy. (Menkes, C.J., et al. La Synoviorthese a
L’acide Osmique Chez L’hemophilie, Rev. Rhum.
40:255, 1973; Oka, M., et al., The Fate and Distribution
of Intra-Articularly Injected Osmium Tetraoxide, Acta
Rheum. Scand., 16:271, 1970; Delbarre, F., et al., La
Synoviorthese par les Radio-Isotopes a la Main et au
Poignet, Rev. Rhum., 40:205, 1973). Some chemical
agents that have been used are thio-tepa (Flatt, A.E.,
Intra-Articular Thio-Tepa in Rheumatoid Disease of
the Hands, Rheumatism, 18:70, 1962; Fearnley, M.D.,
Intra-Articular Thio-Tepa Therapy in Rheumatoid Ar
thritis, Ann. Phys. Med., 7:294, 1963; Zuckner, J., et al.,
Evaluation of Intra-Articular Thio-Tepa in Rheumatoid
Arthritis, Ann. Rheum. Dis., 25:178, 1966; Gross, D.,
Chemische Synovektomie mit Senfgas bei Primar Chronischer Polyarthritis, Z. Rheumforsch, 22:456, 1963;
Mondragon Kalb, M., Thiotepa en al Tratamiento de la
Arthritis Rhumatoide, Medicina, 15:82, 1965), osmic
acid (Menkes, C.J., et al., La Synoviorthese a L’acide
Osmique Chez L’hemophilie, Rev. Rhum., 40:255,1973;
Oka, M., et al., The Fate and Distribution of IntraArticularly Injected Osmium Tetraoxide, Acta Rheum.
Scand., 16:271, 1970; Von Reis, G., et al., Intra-Articular Injections of Osmic Acid in Painful Joint Affections,
Acta Med. Scand. Supp ., 259: 27, 1951; Berglof, F.E.,
Further Studies on the Use of Osmic Acid in the Treat
ment of Arthritis, Acta Rheum. Scand., 10:92, 1964;
Martio, J., et al., Intra-Articular Osmic Acid in Juvenile
Rheumatoid Arthritis, Scand. J. Rheumatol, 1:5, 1972;
Brattstrom, H., et al., Kombinierte Chemische und Op
erative Synovektomie es Kniegelenks, Orthapade, 2:73,
1973; Jakubowski, S., et al., Indikatronen zur Synovek
tomie bei pcP, orthopade, 2:6, 1973), varicoid (Tillman,
K., Chemische Synovektomie, Orthopade, 2:10, 1973)
and gold (Delbarre, F., et al., supra). Radioactive sub
stances include Gold-198, Yttrium-90 citrate, Yttrium90 resin, Rhenium-186, Erbium-169, Yttrium-90 ferric
hydroxide, Radium-224 and Phosphorus-32 chromic
phosphate (Sledge, C.B., supra).
Beta-emitting radionuclides are considered the most
useful for radiotherapeutic applications because of the
moderate linear energy transfer (LET) of the ionizing
particle (electron) and its intermediate range (typically
several millimeters in tissue). In contrast, gamma rays
deliver dosage at lower levels over much greater dis
tances, thus hampering the localization of the dose and
diluting its effect. Alpha particles represent the other
extreme; they deliver very high LET dosage, but have
an extremely limited range and must, therefore, be in
intimate contact with the cells of the tissue to be treated.
In addition, alpha emitters are generally heavy metals,
which limits the possible chemistry and presents undue
hazards from leakage of radionuclide from the area to
be treated.
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It is fortuitous that beta emitters, the most useful
radiotherapeutic radionuclides, are also the ones most
copiously produced by neutron capture in nuclear reac
tors, the most powerful sources of radioisotopes. Reac
tor-produced isotopes number in the thousands, giving
researchers a wide choice of isotopes of various halflives, beta energies, gamma emissions, and chemical
properties. Gamma emissions, while not as useful for
therapy as beta emissions, play an important role in that
they permit the distribution of radioisotope in the body
to be observed using an Anger gamma ray camera or
single photon computed tomography (SPECT) instru
ment. This permits direct observation and, to some
extent, quantification of radionuclide leakage from an
organ or a joint and also provides positive verification
of the potency of joint injection and distribution of the
radionuclide in the research animal.
Treatment of the different depths of diseased syno
vium in joints of disparate size, such as the finger joints
and the knee, requires isotopes of different average beta
range. It is important to achieve a “kill” of sufficient
depth to be efficacious without causing significant ne
crosis of overlying normal tissues.
The effectiveness of a radioisotope depends upon the
fact that it gives off beta radiation which kills tissue
along with the fact that it gives off no alpha and little
gamma radiation. The latter type of radiation penetrates
too far, affecting tissues adversely, whereas beta radia
tion has a short penetration distance, varying in millime
ters for each radioisotope. Radioisotopes also have dif
ferent half-lives, some being far too long or too short for
any practical use. These factors, then, have to be con
sidered in the application of a radioisotope for synoviorthesis.
Sledge et al. (Treatment of Rheumatoid Synovitis of
the Knee with Intra-Articular Injection of Dysprosium165 Ferric Hydroxide Macroaggregates, Arthritis and
Rheumatism, 29(2):153, 1986) have used macroaggre
gates of ferric hydroxide (FHMA) combined with dysprosium-165. This compound does present the problem
of some leakage to local lymph nodes and other tissues
Also, dysprosium-165 has a half-life of 2.3 hours, mak
ing it necessary for the patient to be close to a nuclear
reactor, severely limiting the use of this radioisotope.
Even with these drawbacks, the clinical results were
noteworthy, as 80% of patients treated for chronic
synovitis of the knee with dysprosium-165-FHM A were
improved at one year, and nearly 90% of patients with
stage 1 roentgenographic changes had excellent, good,
or fair results (Sledge, et al., Intra-Articular Radiation
Synovectomy, Clinical Orthopaedics and Related Re
search, 182:37, 1984). These results and the results of
others (Boerbooms, A.M., et al., Radio-Synovectomy in
Chronic Synovitis of the Knee Joint in Patients with
Rheumatoid Arthritis, European Journal of Nuclear
Medicine, 10:446, 1985; Multicentre Trial Group: IntraArticular Radioactive yttrium and Triamcinolone Hexaoetonide: An Inconclusive Trial, Ann. Rheum. Dis.,
43:620, 1984; Kyle, V., et al., Yttrium-90 Therapy and
99mTc Pertechnetate Knee Uptake Measurements in the
Management of Rheumatoid Arthritis, Annals of the
Rheumatic Diseases, 42:132, 1983; Rosenthall, L., Use
of Radiocolloids for Intra-Articular Therapy for Syno
vitis, In Therapy in Nuclear Medicine, Grune and Strat
ton, Inc., New York, 1978, p. 147; Spooren, P. et al.,
Synovectomy of the Knee with 90-Y, European Journal
of Nuclear Medicine, 10:441, 1985) show that radiation
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synoviorthesis has a role in the treatment of inflamma
tory synovitis.
In our copending, coassigned application for U.S.
pat. ser. No. 673,123, filed Nov. 19, 1984, we disclose
5 novel microspheres for use in the radiation therapy of
liver cancer and other cancerous or tumor bearing tis
sue. Such microspheres have not, however, been used
or suggested for use in radiation synovectomy of ar
thritic joints and may not be suitable for use in radiation
10 synovectomy by reason of the radionuclides incorpo
rated therein having relatively long physical half-lives.
There is a continuing need, therefore, for improved
microspheres and methods for radiation synovectomy
of arthritic joints.
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SUMMARY OF THE INVENTION
Among the several objects of the invention may be
noted the provision of novel microspheres for use in
radiation synovectomy of arthritic joints; the provision
of such microspheres containing beta emitting radioiso
topes which have a moderately abundant low energy
gamma photon that is in the energy range used for
nuclear medicine imaging; the provision of such microspheres which are biodegradable and advantageously
gradually dissolve after they are no longer radioactive;
the provision of such microspheres which are prepared
in a nonradioactive form and may then be subjected to
an effective amount of neutron irradiation to produce
microspheres containing the desired beta emitting radi
oisotope; and the provision of methods for carrying out
radiation synovectomy of arthritic joints and for pre
paring biodegradable microspheres for use in radiation
synovectomy. Other objects and features will be in part
apparent and in part pointed out hereinafter.
Briefly, the present invention is directed to novel
radioactive microspheres useful for radiation synovec
tomy of arthritic joints. These radioactive microspheres
comprise a biodegradable or biologically compatible
glass material containing a beta radiation emitting radio
isotope chemically dissolved therein. In a preferred
embodiment, such microspheres have been subjected to
an acid wash to produce a sparingly soluble coating on
their outer surface so that the microspheres gradually
dissolve after they are no longer radioactive.
Another aspect of the invention is the provision of
novel microspheres which are initially nonradioactive
and which, upon being subjected to an effective amount
of neutron irradiation, will produce a beta radiation
emitting radioisotope thereby rendering the micro
spheres suitable for use in radiation synovectomy of
arthritic joints while avoiding the handling of radioac
tive elements during initial production of the microspheres.
A still further aspect of the invention resides in the
provisions of novel methods for carrying out radiation
synovectomy of arthritic joints utilizing the novel radi
oactive microspheres of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS

60

65

FIGS. 1 and 2 are graphs showing the dissolution
(weight loss in mg/cm2) of two different glass composi
tions of the invention in deionized water at 37° C. as a
function of time.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS
In accordance with the present invention has now
been found that certain novel radioactive microspheres
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may be advantageously employed in radiation synovec
age range of about 2 mm. Since dysprosium-165 emits a
tomy of arthritic joints while substantially avoiding
beta particle of slightly lower maximum energy (1.31
systemic leakage of the beta radiation emitting radioiso
MeV) and has proven efficacious in human knee radia
tope from the joint being treated and permitting greater
tion synovectomies, it appears that holmium-166 has
control of the particle size of such microspheres. The 5 sufficient penetration for this application. Ho-166 also
radioactive microspheres of” the invention are prepared
emits an 80.5 Kev gamma-ray in 6.2% abundance and
from novel microspheres which may be manufactured
thus is imageable by conventional techniques.
and sized before radioactivity is induced providing the
Samarium-153 is produced by neutron capture of
advantage of working only with nonradioactive materi
natural or isotopically enriched samarium-152 with
als during initial production of the microspheres.
10
thermal and resonance neutron cross sections of 2 1 0 and
In a first embodiment of the invention, the novel
3,020 bams, respectively. It decays by beta emissions of
radioactive microspheres are comprised of a biodegrad
0.810 MeV (20%), 0.710 MeV (49%), and 0.640 MeV
able glass material selected from the group consisting of
(30%) maximum energies with concomitant ranges of
lithium silicate, lithium aluminosilicate, lithium
about
2.3 mm maximum and 0.8 mm average distance,
aluminoborate, lithium germanate and lithium alumino- 15
respectively. Sm-153 has a physical half-life of 46.27
germanate and containing a beta radiation emitting
hours and produces a highly imageable 103 KeV
radioisotope chemically dissolved in and distributed
gamma ray with an abundance of 29.8%, decaying to
substantially uniformly throughout the glass material,
stable Eu-153.
the radioisotope being samarium-153, holmium-166,
Samarium-153 and holmium-166 are both chemically
erbium-169, dysprosium-165, rhenium-186, rhenium-188 20
compatible and capable of being incorporated into
or yttrium-90. It has been found that lithium silicate,
many types of glass in which no other significant radio
lithium aluminosilicate, lithium aluminoborate, lithium
activities induced by neutron bombardment will be
germanate or lithium aluminogermanate biodegradable
present after about one day of decay. Erbium-169, dys
glasses are particularly suitable for the purposes of the
invention since lithium does not become a gamma emit 25 prosium-165, rhenium-186, rhenium-188 (from rhenium185 and rhenium-187) and yttrium-90 also possess the
ter upon being subjected to neutron irradiation whereas
desired properties rendering them suitable for use as the
sodium, calcium and phosphorus, components of other
radioisotope in this embodiment of the invention.
wise biodegradable glasses, do become gamma emitters
with unacceptably long half-lives upon neutron irradia
As mentioned, in the first embodiment of the inven
tion or become beta emitters which have undesirably 30 tion generally described above, a biodegradable glass
long half-lives or which bond to bone. For example, the
material is selected from the group consisting of lithium
composition of the bioactive and partially biodegrad
silicate, lithium aluminoborate, lithium aluminosilicate,
able glass composition known as “Bioglass” is 45%
lithium germanate and lithium aluminogermanate or the
Si0 2 , 24.5% Na20 , 24.5% CaO and 6 % P 20 5 (Hench,
corresponding potassium glass materials. Such glasses
Ceramic Implants for Humans, Advanced Ceramic 35 may be doped with samarium oxide (Sm20 3 ), holmium
Materials, l(4):306-324, 1986), and this glass is unsuit
oxide (H o20 3) or oxide of erbium, dysprosium, rhenium
able because of the sodium, calcium and phosphorous it
or yttrium in preparing the novel nonradioactive and
contains.
radioactive microspheres of the invention. By way of
Also, while use of the above-noted lithium glass ma
example, such biodegradable glasses so doped may have
terials is preferred, potassium glasses selected from the 40 the following illustrative compositions by weight per
group consisting of potassium silicate, potassium alumi
cent:
nosilicate, potassium aluminoborate, potassium germa
20.1% LaiO-74.9% SiCV5% SmaOs;
nate and potassium aluminogermanate may also be used
21.8% Li20-3.9% Al20 3-69.3% Si0 2-5%Sm 20 3.
in the practice of the invention. While potassium does
19.7% Li20-13.1% B20 3-62.2% Si0 2-5% Sm20 3;
become a gamma emitter upon being subjected to neu 45 It will be understood that other lithium silicate, lithium
tron irradiation, the radioisotope potassium-42 thus
aluminosilicate, lithium aluminoborate, lithium germa
produced has an acceptably short half-life of approxi
nate and lithium aluminogermanate glass materials or
mately 12 hours. Therefore, when such potassium glass
the corresponding potassium glass materials suitably
materials are employed, administration of the radioac
doped with samarium, holmium, erbium, dysprosium,
tive microspheres containing them is delayed for a suffi 50
rhenium or yttrium may also be used in the practice of
cient time to permit the potassium-42 to decay to ac
the
invention.
ceptable levels.
In
a second embodiment of the invention, the novel
The above-noted beta radiation emitting radioiso
radioactive
microspheres are comprised of a biologi
topes are also particularly suitable for use in the present
invention. Samarium-153 (46.3 hr. half-life) and holmi- 55 cally compatible glass material selected from the group
consisting of magnesium aluminosilicate and aluminosil
um-166 (26.8 hr. half-life) can readily be dissolved in
icate glass material and containing a beta radiation emit
silicate, aluminosilicate or aluminoborate glasses, have
ting radioisotope chemically dissolved in and distrib
good activation properties in a nuclear reactor, possess
uted substantially uniformly through the glass material,
imageable gamma rays, exhibit low toxicity and have
half-lives long enough for distribution of the radioactive 60 the radioisotope being samarium-153, holmium-166,
erbium-169, dysprosium-165, rhenium-186 or rheniummicrospheres of the invention containing them.
188 . While such glass materials are not biodegradable,
Holmium-166 is produced by neutron capture on
they are biologically compatible and are useful in the
100% abundant, stable holmium-165 with thermal neu
practice of the invention. Such glass compositions may
tron and resonance neutron cross sections of 61.2 and
670 bams, respectively. It decays with a 26.83 hour 65 be prepared by doping magnesium aluminosilicate or
alumino-silicate glass materials with oxides of samarium
half-life by emission of 1.855 MeV (51%) and 1.776
(Sm20 3), holmium (Ho20 3), erbium (Er20 3), dys
MeV (48%) maximum energy beta particles with a
prosium (Dy 2 0 3), or rhenium (R e02). Illustrative spe
maximum range in water of about 8.0 mm and an aver-
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cific examples of such glass compositions include the
following compositions by weight percent.
20% MgO-21% Al20 3-52% S i0 2-7% Sm20 3.
40% Y2O 3-20% Al2O3-40% Si02.
40% Sm2O 3-20% Al2O3-40% S i02.
5
20% MgO-21% Al20 3-52% S i0 2-7% Ho 20 320% MgO-21% Al20 3-52% Si0 2-7% R e0 2; ’
It will be understood that other magnesium aluminosili
cate or aluminosilicate glass materials suitably doped
with samarium, holmium, erbium, dysprosium or rhe 10
nium may also be used in the practice of the invention.
The microspheres of the present invention may be
prepared from a homogeneous mixture of powders (i.e.
the batch) that is melted to form the desired glass com
position. The exact chemical compounds or raw materi 15
als used for the batch is not critical so long as they
provide the necessary oxides in the correct proportion
for the melt composition being prepared. For example,
if a samarium doped lithium silicate glass is being made,
then Sm20 3, Li2C 0 3 and S i0 2 Powders would be used 20
as the batch raw materials. The purity of each raw
material is typically greater than 99.9%. After either
dry or wet mixing of the powders to achieve a homoge
neous mixture, the mixture may be placed in a platinum
crucible for melting. High purity alumina crucibles can 25
also be used if at least small amounts of alumina can be
tolerated in the glass being made. The raw materials
must not contain impurities that become radioactive
from neutron irradiation.
The crucibles containing the powdered batch are 30
then placed in an electric furnace heated to 1500 to
1600° C. depending upon the composition. In this tem
perature range, the batch melts to form a liquid which is
stirred several times to improve its chemical homogene
ity. The melt should remain at 1500 to 1600° C. until all 35
the solid batch is totally dissolved. This usually requires
2 to 5 hours duration. When melting and stirring is
complete, the crucible is removed from the furnace and
the melt is quickly quenched to a glass by pouring the
melt onto a cold steel plate or into cold clean water. 40
This procedure breaks the glass into fragments, which
aids and simplifies crushing the glass to a fine powder
(less than 400 mesh). The powder is then sized and
spheridized for use.
The quenched and broken glass is first crushed to
45
about minus 100 mesh particle size using a mortar and
pestle. The minus 100 mesh material is then ground
using a mechanized mortar and pestle or ball mill until
it passes a 400 mesh sieve. The minus 400 mesh particles
(37 microns in diameter) may be stored in a dry con
50
tainer until used.
The particles are formed into glass microbeads or
microspheres by introducing the minus 400 mesh parti
cles into a gas/oxygen flame where they are melted and
a spherical liquid droplet is formed by surface tension.
This droplet is rapidly cooled before it touches any 55
solid object so that its spherical shape is retained in the
solid. Just prior to spheridizing, the minus 400 mesh
powder is rescreened through a 400 mesh sieve to de
stroy any large agglomerates that may have formed
during storage. The minus 400 mesh powder is then 60
placed in a vibratory feeder located above the gas/oxygen burner. The powder is slowly vibrated into a verti
cal glass tube which guides the powder particles di
rectly into the hot flame of the gas/oxygen burner. A
typical rate for feeding the powder to the flame is 5 to 65
25 grams/hour with the described apparatus. The flame
of the burner is directed into a small metal container
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which catches the small glass beads or spheres as they
are expelled from the flame.
After spheridization, the glass spheres are collected
and rescreened with a sonic sifter. For use in the present
invention, the fraction in the range of 3 to 30 microns in
diameter is recovered since this is the desirable size for
use in radiation synovectomy of arthritic joints. After
screening, the microspheres in this size range are exam
ined with an optical microscope and are then washed
with a weak acid (HC1, for example), filtered and
washed several times with reagent grade acetone. The
washed beads or spheres are then heated in a furnace in
air to 500-600° C. for 2-6 hours to destroy any organic
material therein.
The final step is to examine a representative sample of
the microspheres in the selected size range or fraction in
a scanning electron microscope. The size, range and
shape of the beads or spheres are evaluated, and the
quantity of undersize beads (less than 3 microns in diam
eter) is determined along with the concentration of
non-spherical particles. The composition of the beads
can be checked by energy dispersive x-ray analysis to
confirm that the composition is correct and that there is
an absence of chemical contamination.
The glass microspheres are then ready for activation
by being subjected to an effective amount of neutron
irradiation which will produce a beta radiation emitting
radioisotope of samarium-153, holmium-166, erbium169, dysprosium-165, rhenium-186, rhenium-188 or yttrium-90, the amount depending upon the particular
isotope of these elements that has been chemically dis
solved and uniformly distributed throughout the glass
material. The resulting radioactive microspheres of the
invention have beta radiation emitting energies highly
suitable for radiation synovectomy of arthritic joints
and also provide gamma ray emissions suitable for nu
clear medicine imaging devices.
In accordance with the invention, the radioactive
microspheres prepared as described may be adminis
tered to the afflicted joints by intra-articular injection or
by other suitable means of administration. The microspheres are believed to be chemically durable in joint
fluids and mechanically contained within the joint cav
ity. Moreover, upon administration, they become dis
tributed reasonably uniformly along the synovial mem
brane and emit beta radiation of sufficient range to fully
or substantially fully irradiate the thickness of the mem
brane without giving significant dosage to more distant
joint structures. Also, inasmuch as the thickness of the
diseased membrane varies in different joints, the present
invention makes possible the preparation of micro
spheres doped with a different energy beta emitter for a
finger joint than for a knee, for example.
Further, the present invention provides smooth mi
crospheres which constitute a preferred shape over
irregular, jagged particles with sharp edges and comers
for the purpose of radiation synovectomy of arthritic
joints. The smooth surface of a sphere should be more
tissue compatible and less irritating than other shapes.
The smooth shape of the microspheres of the invention
should also cause less friction, mechanical wear and
inflammation in a joint with moving parts than irregu
larly shaped particles. Heretofore, radioactive micro
spheres of the type provided by the present invention
have not been available nor have glass microspheres of
this type been injected into arthritic joints of humans or
animals.
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While, as indicated, the microspheres of the present
20% Al2C>3-40% SiC>2. The injections were made in the
invention may be of various sizes, it is preferred for
left stifles (knee) using Angiovist 370 contrast medium
radiation synovectomy of arthritic joints that the micro(diatrizoate meglumine and diatrizoate sodium; Berlex
spheres have a diameter within the range of about 3 to
Laboratories, Incorporated) as a suspending medium,
30 micrometers (microns).
5 with a control injection of Angiovists in the right stifle.
To localize the desired radiation to the affected joint,
The rabbits showed no ill effects whatsoever over peri
the radioactive element is chemically dissolved in a host
ods ranging from 48 hours to three months. Upon sacri
glass material which is insoluble in the body. The es
fice at intervals of 2 to 90 days, the stifles were all dis
cape or leakage of the radioactive material from the
sected and slides prepared of various joint tissues. Ex
joint has been a major problem with other types of 10 amination of the slides revealed microspheres only
materials (e.g. colloids) previously used in this type of
along the synovium with no spheres apparent in the
radiation therapy and an insoluble glass should prevent
Underlying fat tissue or lymph nodes, and no mechani
any leakage since the radioactive material cannot es
cal abrasion or damage to the cartilage or other joint
cape from insoluble glass microspheres. Also, for use in
structures.
human joints, there is a perceived advantage to using 15
Example 2
glass beads or microspheres which gradually dissolve
after they are no longer radioactive, i.e. which are bio
FIGS. 1 and 2 show the dissolution (weight loss in
degradable. Accordingly, in accordance with the pres
mg/cm2) of two different glass compositions as shown
ent invention, it is preferred to employ the biodegrad
thereon in deionized water at 37° C. as a function of
able glass microspheres which are initially insoluble 20 time. The straight lines labeled 3 mos. and 6 mos. desig
during the period of time the bead is radioactive (i.e.
nate the dissolution needed for a 30 micro bead or
few weeks) and which then gradually starts to dissolve
sphere to dissolve in 3 and 6 months, respectively. In
and eventually disappear.
addition to untreated specimens (control), each figure
Biodegradable glass microspheres having such de
also shows the dissolution of specimens of each glass
sired characteristics may be prepared through another 25 composition washed in 1 N HC1 for 4 hours at either 25
aspect of the present invention by treating the aboveor 50° C.
described biodegradable lithium silicate, lithium alumi
The effectiveness of the acid wash in reducing the
nosilicate, lithium aluminoborate, lithium germanate,
dissolution at short times is clearly evident in FIG. 1 for
lithium aluminogermanate or corresponding potassium
the specimen washed in HC1 at 25° C. In contrast to the
glass microspheres in such a way as to form an insoluble 30 unwashed control which showed an immediate weight
or sparingly soluble coating on its outer surface. This
loss, the sample washed in acid at 25° C. did not show
can be done by washing such glasses in common acids
any detectable weight loss for more than one week in
such as hydrochloric acid, nitric acid or sulfuric acid
deionized water. After about one week, the sample then
and thereby replace the lithium or potassium ions on the
began to dissolve as desired. Similar results are given in
outer surface with protons or H 3O+. The results of this 35
FIG. 2, except that acid washing at 50° C. was more
dealkalization process is to produce a thin layer (skin)
effective for this glass because of its different composi
on the surface of the glass beads or microspheres whose
tion.
solubility is less than of the underlying glass. A glass
These studies show that acid washing produces an
bead with such a dealkalized surface initially dissolves
insoluble
surface skin which yields the dissolution char
slowly until the more durable outer surface layer is 40
acteristics needed for radioactive, biodegradable glass
dissolved, and then starts to dissolve faster as the less
microspheres for use in human joints.
durable, underlying glass is exposed to the surrounding
media.
Example 3
Thus, washing glass microspheres of the invention in
A.
SAMPLE
PREPARATION
common acids is an exemplary and practical means of 45
The glass compositions in the following table were
achieving the desired dissolution characteristics re
quired for radioactive, biodegradable glass micro
prepared from reagent grade chemicals. Batches yield
spheres for use in human joints. It will be understood by
ing 50 grams of glass were melted in platinum crucibles
those skilled in the art that various factors are important
in an electric furnace at approximately 1350° C. The
to the dissolution characteristics of the dealkalized sur 50 melt was held at 1350° C. for 1 to 2 h for fining and
face or skin. These are: ( 1) the starting glass composi
homogenization and then cast into steel molds to form
tion, especially the amount of alkali ion (i.e. lithium or
bars measuring approximately l x 1X1X8 cm which
potassium) present; (2 ) concentration and type of acid
were annealed at 500° C. for 30 min. and then slowly
employed; (3) temperature of the acid; (4) time of acid
cooled to room temperature. Slabs approximately
treatment; and (5) heat treatment of dealkalized surface 55 0 .2 X 1 X 1 cm were cut from the bars and ground to
after acid wash. It will also be understood by those
rectangular shape using 180 grit silicon carbide paper.
skilled in the art that in addition to acid washing, other
procedures such as heating a glass in various gases such
COMPOSITION OF GLASSES
as SO2 and F 2 can be used to produce a more chemically
Batch Composition (Weight %)
durable dealkalized skin on the lithium and potassium 60
Glass
S i02
Li20
s m 2o 3
a i 2o 3
glasses described above.
LSI
74.9
20.1
0.0
The following examples further illustrate the inven
5.0
LS3
69.3
21.8
3.9
5.0
tion.
Example 1
31 rabbits were injected with about 5 mg each of
non-radioactive glass microspheres (20-30 microns in
size) having the composition by weight: 40% Y2O 3-

65

A portion of the LSI glass was broken and ground to
—200 mesh and wet milled for 6 h with methanol. The
powder was then dried and screened through a 325
mesh sieve. The —325 mesh glass powder was slowly

11

5,011,797

fed into an oxygen/propane flame where surface ten
sion caused the molten particles to become spheres.

12

ished to 1 micron using silicon carbide polishing paper
and finally one micron AI2O 3. These slabs were left
untreated, treated in acid, or treated in acid followed by
B. SURFACE TREATMENTS
heat treatment (LSI; 350° C. for 30 minutes, LS3: 400°
1. Sulfur Dioxide Gas
5 C. for 45 minutes). These samples were examined by
SEM to determine if there was any change in the sur
The glass slabs were placed in a tube furnace at either
face due to washing in acid or washing in acid followed
400 or 500° C'. SO2 gas was bubbled through Water at
by heat treatment.
25° C. at an approximate rate of one bubble per second
before flowing through the furnace. The treatment
E. RESULTS AND CONCLUSIONS
times were 90 min. at 400° C. and 15 or 45 min. at 500° 10
LSI glass which contains 74.9% Si02, 20.1% Li20,
C. After removal from the furnace, the slabs were
and 5.0% S1X12O 3 (weight %) is well suited for micro
cooled, rinsed in distilled water to remove any lithium
sulphate formed on the surface, and dried in an oven at
spheres that could be irradiated to treat rheumatoid
100° C.
arthritis. Acid washing followed by heating LSI re
15 duced the dissolution to zero. Glasses acid washed and
2. Washing in HC1
heated at 400° C. remained insoluble after 6 months.
The glass was placed in a 0.1N HC1 solution in a
LSI glass acid washed then heated for 10 min. at 350° C.
beaker, magnetically stirred, rinsed in distilled water,
remained insoluble for 4 weeks and then began to dis
and dried in air at 100° C. Initially, the effect of acid
solve at approximately half of the rate calculated for a
washing on the glasses for 2,4, 6 or 8 h at 25° C., 50° C., 20 30 micron sphere to dissolve in 6 months. If this glass
or 75° C. was examined. The time and temperature
continued to dissolve at this rate, then a 30 micron
which gave the longest delay before dissolution com
sphere treated in this way should be totally dissolved in
menced for LSI was 4 h at 25° C. an for LS3 was 4 h at
12 months. Acid washing followed by heat treatment of
50° C. These times and temperatures were used in subse
LSI glass for 10 min. for 350° C. appears to create a
25
quent heat treatments.
temporarily insoluble surface layer which should pre
3. Washing in HC1 Followed by Heat Treatment
vent the release of radioactive Sm-153.
After washing in 0.1 N HC1 acid, the glass slabs were
SEM photographs of polished LS3 glass shows that
heated on a steel plate in a furnace to 350 or 400° C. At
acid washing followed by heating causes the surface to
350° C., the slabs were heated for 10 or 30 min. and at
crack. This is probably due to a difference in thermal
400° C., the slabs were heated for 10, 30, 45, 60, or 90 30 expansion between the bulk glass and the dealkalyzed
min. Microspheres of LSI were heated at 350° C. for 30
layer. Acid washed then heated LS3 glasses began to
min.
dissolve immediately confirming no protective layer
was created. In LS3 glass acid washed then heated at
C. CHEMICAL DISSOLUTION
400°
C., the initial dissolution rate paralleled the acid
MEASUREMENTS
35
washed glass. After a few weeks, the dissolution de
After surface treatments, the glass slabs were
creased to almost zero, suggesting the corrosion process
weighed and their exact dimensions measured before
caused a protective layer to develop.
placing them in polyethylene bottles containing 125 mL
Washing LSI and LS3 glass in 0.1N HC1 delays the
of distilled water (pH=7). The bottles were placed in
an oven at 37° C., which is the temperature of the 40 dissolution of LS3 for 5 days and of LSI for 7 days.
Dissolution then begins at approximately the same rate
human body. The weight change of each slab was mea
as the untreated glass.
sured periodically by removing the slab from the bottle,
Exposure to hot sulfur dioxide gas decreases the dis
drying it in an oven at 100° C., and weighing.
solution of LSI glass in water at 37° C. but does not
The average dissolution, D, of each sample was cal
45 significantly affect the dissolution of LS3. No delay in
culated from the equation
dissolution occurred for either glass. Decreasing the
temperature of the SO2 treatment may facilitate the
D = (W 0- W ) /A
dealkalyzing reactions of the SO2 and improve the
chemical durability of the surface.
where W0was the initial weight of the original slab,
SEM photographs confirm that the acid washed then
W was the current weight of the slab, and A was the 50
heated slabs of LSI which had a zero dissolution rate
surface area of the slab. The dissolution was plotted
against time.
show no effect of corrosion, while the acid washed and
untreated slabs showed cracking after two weeks in
Approximately 20 mg of microspheres made from the
water.
LSI glass were placed in polyethylene bottles contain
ing 25 mL of distilled water and placed in an oven at 37° 55
Example 4
C. The microspheres were removed after 3 weeks for
SEM analysis.
About 10 mg. of non-biodegradable glass micro
spheres (10-20 microns in size) having the composition
D. SEM ANALYSIS
by weight: 20% MgO-21% Al203-52% Si02-7%
Selected microspheres and slabs were mounted on a 60 Sm2 0 3 , were irradiated 10 minutes in a neutron flux of
steel cylinder for SEM analysis. The slabs were broken
4E13/square cm/sec to make about 300 microcuries of
and one piece was mounted to observe the corroded
Sm-153. The microspheres were irradiated in sealed,
surface and the other to observe the fresh fracture sur
high density polyethylene vials having a volume of
face. The mounted slabs and microspheres were vapor
slightly more than 1 cc and drawn into 1 cc tuberculin
coated with palladium.
65 syringes using Angiovist contrast medium as a suspend
Because the as-cut slabs had a very rough surface,
ing agent and injected into the stifles of healthy rabbits.
polished slabs were used to see the effects of surface
Serial imaging was performed to ascertain leakage.
treatments. The surface of slabs of each glass was pol
Significant leakage was observed down the leg of the
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first four rabbits, but this appeared to occur due to
leakage out of the injection puncture and possible tear
in the joint capsule. A fifth rabbit injected through the
cartilage in the front of the knee (i.e. through a thicker,
self-sealing portion of the joint) exhibited no leakage.
In view of the above, it will be seen that the several
objects of the invention are achieved and other advanta
geous results attained.
As various changes could be made in the above prod
ucts and methods without departing from the scope of
the invention, it is intended that all matter contained in
the above description or shown in the accompanying
drawings shall be interpreted as illustrative and not in a
limiting sense.
What is claimed is:
1. A nonradioactive microsphere adapted for radia
tion synovectomy on arthritic joints in a mammal com
prising a biologically compatible glass material selected
from the group consisting of magnesium aluminosilicate
and aluminosilicate and containing an isotope selected
from the group consisting of samarium, holmium, er
bium, dysprosium, and rhenium chemically dissolved in
and distributed substantially uniformly throughout said
glass material and which, upon being subjected to an
effective amount of neutron irradiation, will produce a
beta emitting radioisotope selected from the group con
sisting of samarium-153, holmium-166, erbium-169, dys
prosium-165, rhenium-186 and rhenium-188.
2. A microsphere as set forth in claim 1 wherein said
glass material is magnesium aluminosilicate and said
radioisotope is samarium-153.
3. A microsphere as set forth in claim 1 wherein said
glass material is aluminosilicate and said radioisotope is
samarium-153.
4. A microsphere as set forth in claim 1 wherein said
glass material is magnesium aluminosilicate and said
radioisotope is holmium-166.
5. A microsphere as set forth in claim 1 wherein said
glass material is aluminosilicate and said radioisotope is
holmium-166.
6 . A microsphere as set forth in claim 1 wherein said
microsphere has a diameter in the range of about 3 to
about 30 micrometers.
7. A microsphere as set forth in claim 1 wherein the
composition of said microsphere is approximately 2 0 %
by weight MgO, approximately 21% by weight AI2O 3,
approximately 52% by weight SiC>2 and approximately
7% by weight Sm2 0 3 .
8 . A microsphere as set forth in claim 1 wherein the
composition of said microsphere is approximately 2 0 %
by weight AI2O 3, approximately 40% by weight SiC>2
and approximately 40% by weight Sm2 0 3 -
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9. A nonradioactive microsphere adapted for radia
tion synovectomy of arthritic joints in a mammal com
prising a biodegradable glass material selected from the
group consisting of lithium silicate, lithium aluminosili
cate, lithium aluminoborate, lithium germanate, lithium
aluminogermanate, potassium silicate, potassium alumi
nosilicate, potassium aluminoborate, potassium germa
nate and potassium aluminogermanate and containing
an isotope selected from the group consisting of samar
ium, holmium, erbium, dysprosium, rhenium and yt
trium chemically dissolved in and distributed substan
tially uniformly throughout said glass material and
which, upon being subjected to an effective amount of
neutron irradiation, will produce a beta radiation emit
ting radioisotope selected from the group consisting of
samarium-153, holmium-166, erbium-169, dysprosium165, rhenium-186, rhenium-188 and yttrium-90.
10. A microsphere as set forth in claim 9 wherein said
glass material is lithium silicate and said radioisotope is
samarium-153.
11. A microsphere as set forth in claim 9 wherein said
glass material is lithium aluminosilicate and said radioi
sotope is samarium-153.
12. A microsphere as set forth in claim 9 wherein said
glass material is lithium aluminoborate and said radioi
sotope is samarium-153.
13. A microsphere as set forth in claim 9 wherein said
glass material is lithium silicate and said radioisotope is
holmium-166.
14. A microsphere as set forth in claim 9 wherein said
glass material is lithium aluminosilicate and said radioi
sotope is holmium-166.
15. A microsphere as set forth in claim 9 wherein said
glass material is lithium aluminoborate and said radioi
sotope is holmium-166.
16. A microsphere as set forth in claim 9 wherein said
microsphere has a diameter in the range of about 3 to
about 30 micrometers.
17. A microsphere as set forth in claim 9 wherein the •
composition of said microsphere is approximately
20.1% by weight Li2 0 , approximately 74.9% by weight
SiC>2 and approximately 5% by weight Sm 2 0 3 .
18. A microsphere as set forth in claim 9 wherein the
composition of said microsphere is approximately
21.8% by weight Li2 0 , approximately 3.9% by weight
AI2O 3, approximately 69.3% by weight Si0 2 and ap
proximately 5% by weight S1TI2O 3.
19. A microsphere as set forth in claim 9 wherein the
composition of said microsphere is approximately
19.7% by weight Li2 0 , approximately 13.1% by weight
B2O 3, approximately 62.2% by weight Si0 2 and ap
proximately 5% by weight Sm2 0 3 .
* * * * *

